focus -WSS

focus

author：focus 2025-10-01 00:14:20 - browse：52

PHILADELPHIA — Novo Nordisk, which has dominated the diabetes and obesity markets with its blockbuster drugs Ozempic and Wegovy, now also wants to be a major player in heart disease.

The landmark Select trial presented over the weekend — which showed Wegovy significantly cut the risk of heart complications — is just one of many efforts by the Danish drugmaker to expand into the cardiovascular space. It’s also developing several treatments specific to heart disease and is acquiring a medication for high blood pressure.

“We have a clear vision of being an established cardiovascular company, just as we see ourselves as leaders in diabetes and obesity,” Martin Lange, Novo’s executive vice president of development, said in an interview here at the American Heart Association conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： UnitedHealth quietly bought dozens of outpatient centers

hotspot

WSS

Testing for cancer recurrence creates a new limbo for patients

WHO may add ‘noma' to its list of neglected tropical diseases

Novo Nordisk obesity pill bests Wegovy in early trial

How to bring more disabled researchers into academia

What it’s like to watch children die of measles

Telehealth options flood the market as retailers push virtual care

entertainment

focus

knowledge

Drug repurposing or repositioning? The language matters

Air quality improving but still lags in Black, Hispanic communities

ChatGPT in medicine: STAT answers readers' burning questions

Cassava reveals details — and problems — with Alzheimer's study

United colonoscopy coverage change 'may cost lives,' doctors say

Biden's order seeks to regulate AI risk without stifling innovation

Medicare proposal to cover medical devices draws a mixed reaction

A deep dive into Applied Therapeutics’ data, and questions on Cassava

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

CDC marks new Covid

leisure time

Change Healthcare cyberattack prompts Medicare loan program

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Eli Lilly to pay $200M for Beam’s stake in gene

How to bring more disabled researchers into academia

A deep dive into Applied Therapeutics’ data, and questions on Cassava

IVF, abortion rights issues kick off Biden’s State of the Union

leisure time

hotspot

hotspot

focus